Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma (2017)
Attributed to:
MICA: Immunotherapy for oral cancer prevention and treatment
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1056/nejmoa1709030
PubMed Identifier: 28891423
Publication URI: http://europepmc.org/abstract/MED/28891423
Type: Journal Article/Review
Parent Publication: New England Journal of Medicine
Issue: 19
ISSN: 0028-4793